New U.S. Patent Issued To Dyadic International U.S. Patent No. 8,551,751 B2 -- "BX11 Enzymes Having Xylosidase Activity"
JUPITER, Fla., November 7, 2013 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has been issued U.S. Patent No. 8,551,751 B2 entitled, "BX11 Enzymes Having Xylosidase Activity" by the United States Patent and Trademark Office ("USPTO").
The invention relates to methods of developing and producing novel enzymes, more specifically for the development of a variety of fungal enzymes. Also described in the patent is the encoding of nucleic acid molecules for such enzymes, compositions, recombinant, and genetically modified host cells, and methods of use.
In addition, the patent also addresses methods to convert lignocellulosic biomass into fermentable sugars with enzymes that degrade the lignocellulosic material and novel combinations of enzymes, including those that provide a synergistic release of sugars from plant biomass. Large amounts of carbohydrates in plant biomass provide a plentiful source of potential energy in the form of sugars that can be utilized to produce biofuels such as Cellulosic Ethanol and a variety of bio-based chemicals. Additionally, the patent addresses methods to use the novel enzymes and compositions of such enzymes in a variety of other processes, including washing of clothing, detergent processes, biorefining, deinking and biobleaching of paper and pulp, and treatment of waste streams.
Dyadic's President and CEO, Mark Emalfarb, stated, "This latest patent builds upon our family of patents that address the conversion of lignocellulosic biomass into fermentable sugars for the production of renewable biofuels and bio-based chemicals using our proprietary C1 technology. This latest patent adds to our comprehensive IP portfolio further protecting our C1 protein expression system and the products derived therefrom, which continues to attract blue chip customers, partners, and collaborators."
This patent is the thirteenth U.S. patent issued to Dyadic adding to its portfolio of 41 international patents, 23 pending international and 11 pending U.S. patent applications which cover various features of Dyadic's proprietary technologies.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries.
Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.
SOURCE Dyadic International, Inc.